(Reuters) – The pause of AstraZeneca Plc’s coronavirus vaccine trials due to an unexplained illness in a study participant shows that safety of vaccines will not be compromised, the head of the National Institutes of Health told a U.S. Congress panel on Wednesday.
AstraZeneca Plc said it had paused global trials, including large late-stage trials, of the experimental vaccine following the development to allow an independent committee to review safety data.
The NIH is providing funding for the company’s vaccine trial.
(Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)
